A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Live

Grants and Contracts Details

StatusActive
Effective start/end date1/31/223/21/23

Funding

  • Pharmaceutical Research Associates: $19,334.00